Brain atrophy and patch-based grading in individuals from the CIMA-Q study: a progressive continuum from subjective cognitive decline to AD.,Scientific Reports

当前位置： X-MOL 学术 › Sci. Rep. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Brain atrophy and patch-based grading in individuals from the CIMA-Q study: a progressive continuum from subjective cognitive decline to AD.
Scientific Reports ( IF 3.8 ) Pub Date : 2019-09-19 , DOI: 10.1038/s41598-019-49914-3
Christine Marcotte ₁ , Olivier Potvin ₁ , D Louis Collins _{2,

3} , Sylvie Rheault _{4,

5} , Simon Duchesne _{1,

3,

6}

Affiliation

It has been proposed that individuals developing Alzheimer's disease (AD) first experience a phase expressing subjective complaints of cognitive decline (SCD) without objective cognitive impairment. Using magnetic resonance imaging (MRI), our objective was to verify whether SNIPE probability grading, a new MRI analysis technique, would distinguish between clinical dementia stage of AD: Cognitively healthy controls without complaint (CH), SCD, mild cognitive impairment, and AD. SNIPE score in the hippocampus and entorhinal cortex was applied to anatomical T1-weighted MRI of 143 participants from the Consortium pour l'identification précoce de la maladie Alzheimer - Québec (CIMA-Q) study and compared to standard atrophy measures (volumes and cortical thicknesses). Compared to standard atrophy measures, SNIPE score appeared more sensitive to differentiate clinical AD since differences between groups reached a higher level of significance and larger effect sizes. However, no significant difference was observed between SCD and CH groups. Combining both types of measures did not improve between-group differences. Further studies using a combination of biomarkers beyond anatomical MRI might be needed to identify individuals with SCD who are on the beginning of the clinical continuum of AD.

中文翻译：

CIMA-Q 研究中个体的脑萎缩和基于斑块的分级：从主观认知衰退到 AD 的渐进连续体。

有人提出，患有阿尔茨海默病（AD）的个体首先会经历一个表达主观认知下降（SCD）但没有客观认知障碍的阶段。使用磁共振成像 (MRI)，我们的目的是验证 SNIPE 概率分级（一种新的 MRI 分析技术）是否能够区分 AD 的临床痴呆阶段：无主诉的认知健康对照 (CH)、SCD、轻度认知障碍和 AD 。海马和内嗅皮层的 SNIPE 评分适用于来自魁北克阿尔茨海默病识别联盟 (CIMA-Q) 研究的 143 名参与者的解剖 T1 加权 MRI，并与标准萎缩测量（体积和皮质厚度）进行比较）。与标准萎缩测量相比，SNIPE 评分对于区分临床 AD 似乎更敏感，因为组间差异达到更高的显着性水平和更大的效应量。然而，SCD 组和 CH 组之间没有观察到显着差异。结合两种类型的措施并没有改善组间差异。可能需要使用解剖 MRI 之外的生物标志物组合进行进一步研究，以识别处于 AD 临床连续体开始阶段的 SCD 患者。

更新日期：2019-09-19

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南